‘Low-T’ Drugs Need Randomized CV Safety Trials, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committees also vote to change indication of testosterone replacement therapies, saying new trials are needed if sponsors want to win the old claims back.
You may also be interested in...
Clarus Keeping Commercial Options Open For Oral Testosterone Jatenzo
Jatenzo – the first oral testosterone cleared by US FDA – will compete against injectable and topical formulas in a field that has suffered safety worries in the past. Clarus has a jump on oral rival Lipocine.
AbbVie AndroGel Jury Verdict Targets 'Low T' Promotion
In first bellwether trial in testosterone replacement therapy litigation, jury issues $150m verdict against AbbVie for fraudulent misrepresentation of AndroGel.
FDA/Industry Dispute On Hypogonadism Drug Efficacy Endpoints To Get Panel Review
Clinical trials should go beyond merely demonstrating maintenance of spermatogenesis, US FDA says, but drug developers assert an increase in serum testosterone levels and/or improvement or maintenance of sperm concentration are appropriate clinical measures to support approval.